Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer

Nature Communications

Volumn 4, Issue , 2013, Pages

  Johansson, Henrik J ^a   Sanchez, Betzabe C ^a   Mundt, Filip ^a   Forshed, Jenny ^a   Kovacs, Aniko ^b   Panizza, Elena ^a   Hultin Rosenberg, Lina ^a   Lundgren, Bo ^c   Martens, Ulf ^c   Máthé, Gyöngyvér ^b   Yakhini, Zohar ^d,e   Helou, Khalil ^b   Krawiec, Kamilla ^f   Kanter, Lena ^a   Hjerpe, Anders ^a   Stål, Olle ^g   Linderholm, Barbro K ^a,b   Lehtiö, Janne ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c SCIENCE FOR LIFE LABORATORY   (Sweden)

^d Agilent Laboratories Israel   (Israel)

^e TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AFIMOXIFENE; ESTROGEN RECEPTOR ALPHA; RETINOIC ACID RECEPTOR ALPHA; TAMOXIFEN;

BIOCHEMISTRY; BIOMARKER; CANCER; CYTOLOGY; DISEASE TREATMENT; DRUG RESISTANCE; GENE EXPRESSION; LIGAND; MEDICINE; PROTEIN; SURVIVAL; WOMENS HEALTH;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER SCREENING; CANCER SURVIVAL; CELL PROLIFERATION; CELL STRAIN MCF 7; COHORT ANALYSIS; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEOMICS; QUANTITATIVE ANALYSIS; RECURRENCE FREE SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGAN SPECIFICITY; RECEPTORS, RETINOIC ACID; SURVIVAL ANALYSIS; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84880828042     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms3175     Document Type: Article

References (45)

1. Colditz, G. A. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J. Natl. Cancer Inst. 90, 814-823 (1998).
2. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005).
3. Musgrove, E. A. & Sutherland, R. L. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 9, 631-643 (2009).
4. Michalides, R. et al. Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell 5, 597-605 (2004).
5. van Agthoven, T. et al. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J. Clin. Oncol. 27, 542-549 (2009).
6. van Agthoven, T. et al. Functional identification of genes causing estrogen independence of human breast cancer cells. Breast Cancer Res. Treat. 114, 23-30 (2009).
7. van Agthoven, T., Godinho, M. F., Wulfkuhle, J. D., Petricoin, 3rd E. F. & Dorssers, L. C. Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines. Int. J. Cancer 131, 1998-2007 (2012).
8. Linderholm, B. et al. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J. Clin. Oncol. 18, 1423-1431 (2000).
9. Linderholm, B. K. et al. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res. 61, 2256-2260 (2001).
10. Aesoy, R. et al. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells. Mol. Cancer Res. 6, 1630-1638 (2008).
11. Hua, S., Kittler, R. & White, K. P. Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell 137, 1259-1271 (2009).
12. Ross-Innes, C. S. et al. Cooperative interaction between retinoic acid receptoralpha and estrogen receptor in breast cancer. Genes Dev. 24, 171-182 (2010).
13. Altucci, L., Leibowitz, M. D., Ogilvie, K. M., de Lera, A. R. & Gronemeyer, H. RAR and RXR modulation in cancer and metabolic disease. Nat. Rev. Drug. Discov. 6, 793-810 (2007).
14. Decensi, A. et al. Randomized double-blind 2 - 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. J. Clin. Oncol. 27, 3749-3756 (2009).
15. Gonzalez-Angulo, A. M., Hennessy, B. T. & Mills, G. B. Future of personalized medicine in oncology: a systems biology approach. J. Clin. Oncol. 28, 2777-2783 (2010).
16. Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869-10874 (2001).
17. Sotiriou, C. & Pusztai, L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 360, 790-800 (2009).
18. Symmans, W. F. et al. Genomic index of sensitivity to endocrine therapy for breast cancer. J. Clin. Oncol. 28, 4111-4119 (2010).
19. Schwanhausser, B. et al. Global quantification of mammalian gene expression control. Nature 473, 337-342 (2011).
20. Altelaar, A. F., Munoz, J. & Heck, A. J. Next-generation proteomics: towards an integrative view of proteome dynamics. Nat. Rev. Genet. 14, 35-48 (2013).
21. Brunner, N. et al. MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res. 53, 3229-3232 (1993).
22. Linderholm, B., Lindh, B., Tavelin, B., Grankvist, K. & Henriksson, R. p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. Int. J. Cancer 89, 51-62 (2000).
23. Hua, S. et al. Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Mol. Syst. Biol. 4, 188 (2008).
24. Saito, A. et al. All-trans retinoic acid induces in vitro angiogenesis via retinoic acid receptor: possible involvement of paracrine effects of endogenous vascular endothelial growth factor signaling. Endocrinology 148, 1412-1423 (2007).
25. Godinho, M. F. et al. BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib. Br. J. Cancer 107, 947-955 (2012).
26. Lim, J. S., Park, S. H. & Jang, K. L. All-trans retinoic acid induces cellular senescence by up-regulating levels of p16 and p21 via promoter hypomethylation. Biochem. Biophys. Res. Commun. 412, 500-505 (2011).
27. Park, S. H., Lim, J. S. & Jang, K. L. All-trans retinoic acid induces cellular senescence via upregulation of p16, p21, and p27. Cancer Lett. 310, 232-239 (2011).
28. Lonard, D. M. & O'Malley, B. W. The expanding cosmos of nuclear receptor coactivators. Cell 125, 411-414 (2006).
29. Tanaka, T., Rodriguez de la Concepcion, M. L. & De Luca, L. M. Involvement of all-trans-retinoic acid in the breakdown of retinoic acid receptors alpha and gamma through proteasomes in MCF-7 human breast cancer cells. Biochem. Pharmacol. 61, 1347-1355 (2001).
30. Laursen, K. B., Wong, P. M. & Gudas, L. J. Epigenetic regulation by RARalpha maintains ligand-independent transcriptional activity. Nucleic. Acids. Res. 40, 102-115 (2012).
31. Hurtado, A. et al. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456, 663-666 (2008).
32. Germain, P. et al. Differential action on coregulator interaction defines inverse retinoid agonists and neutral antagonists. Chem. Biol. 16, 479-489 (2009).
33. Lu, Y., Bertran, S., Samuels, T. A., Mira-y-Lopez, R. & Farias, E. F. Mechanism of inhibition of MMTV-neu and MMTV-wnt1 induced mammary oncogenesis by RARalpha agonist AM580. Oncogene 29, 3665-3676 (2010).
34. Hirokawa, Y., Arnold, M., Nakajima, H., Zalcberg, J. & Maruta, H. Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance. Cancer Biol. Ther. 4, 956-960 (2005).
35. Fan, J. et al. ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. J. Cancer Res. Clin. Oncol. 134, 883-890 (2008).
36. Scott, S. M., Brown, M. & Come, S. E. Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer. Expert. Opin. Drug. Saf. 10, 819-826 (2011).
37. Hu, X. F. et al. Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780. Int. J. Cancer 55, 873-876 (1993).
38. Veronesi, U. et al. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann. Oncol. 17, 1065-1071 (2006).
39. Connolly, R., Nguyen, N. K. & Sukumar, S. Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment. Clin. Cancer Res. 19, 1651-1659 (2013).
40. Eriksson, H. et al. Quantitative membrane proteomics applying narrow range peptide isoelectric focusing for studies of small cell lung cancer resistance mechanisms. Proteomics 8, 3008-3018 (2008).
41. Forshed, J. et al. Enhanced information output from shotgun proteomics data by protein quantification and peptide quality control (PQPQ). Mol. Cell Proteomics 10, 010264 (2011).
42. McShane, L. M. et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur. J. Cancer 41, 1690-1696 (2005).
43. Sanchez, B. C. et al. Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF. Eur. J. Cancer 46, 1580-1587 (2010).
44. Linderholm, B. K., Hellborg, H., Johansson, U., Skoog, L. & Lehtio, J. Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer. Breast. Cancer Res. Treat. 125, 457-465 (2011).
45. Vizcaino, J. A. et al. The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013. Nucleic Acids Res. 41, D1063-D1069 (2013).